Drugs Made In America Acquisition II Corp.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-Q
Period ended 2026-03-31; filed 2026-05-14.
0001213900-26-056651
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsCurrent report: 10-Q
Period ended 2026-06-30; filed 2026-08-14.
0001213900-26-090017
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 37 previous paragraphs and 39 current paragraphs.
34 unchanged; 3 reworded; 0 added; 0 removed; 0 previous and 2 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Reworded paragraphs (3)
Previous wording
For the three months ended March 31, 2026, we had net income of $4,337,820, which consists of general and administrative costs of $132,030, offset by interest earned on cash and investments held in the trust account of $4,439,850 and a $30,000 gain from the recovery of credit losses.
Current wording
For the six months ended June 30, 2026, we had net income of $8,734,276, which consists of general and administrative costs of $244,257, offset by interest earned on cash and investments held in the trust account of $8,948,533 and a $30,000 gain from the recovery of credit losses.
Previous wording
For the three months ended March, 31 2025, we had a net loss of $59,327, which consists entirely of general and administrative costs.
Current wording
For the three months ended June, 30 2025, we had a net loss of $38,073, which consists entirely of general and administrative costs.
Previous wording
As of March 31, 2026 and December 31, 2025 we had cash of $347,720 and $223, respectively. Until the consummation of the Initial Public Offering, our only source of liquidity was an initial purchase of ordinary shares by the sponsor and loans from our sponsor.
Current wording
As of June 30, 2026 and December 31, 2025 we had cash of $174,974 and $223, respectively. Until the consummation of the Initial Public Offering, our only source of liquidity was an initial purchase of ordinary shares by the sponsor and loans from our sponsor.
Rearranged current paragraphs (2)
Current report — wording carried from elsewhere
For the three months ended June 30, 2026, we had net income of $4,396,456, which consists of general and administrative costs of $112,227, offset by interest earned on cash and investments held in the trust account of $4,508,683.
Current report — wording carried from elsewhere
For the six months ended June, 30 2025, we had a net loss of $97,400, which consists entirely of general and administrative costs.